ECTRIMS 2016: Biogen Makes Headway in MS Remyelination Studies

20 Sep 2016

• By John Davis

Biogen has identified the type of MS patient likely to respond to its remyelination approach with the investigational MAb opicinumab, even though its Phase II SYNERGY trial missed its primary endpoint.

High quality 3d render of nerve cells, concept for Neurologic Diseases, tumors and brain surgery. — Nerve Cells • Source: Shutterstock

Biogen has received a clutch of useful data from the initially disappointing SYNERGY trial, and is now evaluating the design of further possible Phase II clinical studies of opicinumab, a potential myelin repair agent for the treatment of multiple sclerosis.

“What was important about the study was that we were trying to identify, for the first time, patients who might...